Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
Apogee data drive hype as threat to Lilly, Sanofi becomes clear
Analysts doubled their peak sales forecast to $5.2 billion in the belief zumilokibart will become the first-line treatment for most eczema patients.
Nick Paul Taylor
Mar 23, 2026 9:00am
Lilly partner sees weight loss potential in hibernating animals
Mar 19, 2026 10:00am
Lilly triple-G bet sees 16.8% weight loss in ph. 3 diabetes test
Mar 19, 2026 6:45am
Crossbow hits $77M series B round to bankroll quiver of T-Bolts
Mar 18, 2026 10:50am
J&J changes New York state of mind, closing JLABS site
Mar 17, 2026 11:20am
Roche inks Nvidia expansion to bolster AI factory
Mar 16, 2026 5:58pm
